Twitxy Saved

Andreas Fouras

Verified account This account is verified. Learn more

@AFouras

Entrepreneur, inventor, working at intersection of engineering and healthcare
4DMedical 4DMedical.com Joined April 2013
113 Following 335 Followers 184 Posts

Latest posts 5

Andreas Fouras Verified account @AFouras
I'm really pleased to share a new Board appointment for @4DMedicalXV - Brett Sandercock joins us from today as an independent Non-Executive Director. Brett brings more than 30 years of finance leadership in global healthcare technology. He spent 27 years at ResMed (NYSE:RMD, ASX:RMD), including 20 years as Chief Financial Officer from 2006 until his retirement in May this year.

Brett has lived the journey we are on. At ResMed he helped take an Australian respiratory technology company and build it into a global leader, through US market expansion, reimbursement, M&A and two decades of disciplined capital allocation. As we scale CT:VQ® across the US and Europe, and integrate our recent acquisitions, that experience is directly relevant to the decisions in front of us.

Few executives combine his commercial judgement with such a deep understanding of healthcare technology, and I look forward to working closely with him.

The full announcement is here: asx.api.cmfyapp.com/asx-research/1…
Andreas Fouras Verified account @AFouras
Today we held our 2026 Annual General Meeting. FY26 was been a big year for @4DMedicalXV (ASX:4DX), and we finished it as the best-performing stock on the S&P/ASX 200, up nearly 1,800%.

That result belongs to our people. We structure pay so our team shares in the success of the business, and when the share price rises they are rewarded alongside our shareholders.

1. Our team delivered the year's gains

CT:VQ® moved into clinical use at Stanford, Cleveland Clinic, UC San Diego Health, University of Miami and University of Chicago.

Our team grew to 181 people across seven regions to meet that demand.
2. We have used equity in pay for years
Options and performance rights have long been part of how we pay our team.
We report every grant and the performance measures behind it in our Annual Report.
3. Our priorities for the year ahead
Rolling out CT:VQ® across U.S. Academic Medical Centres, health systems and radiology networks, supported by our Philips agreement.
Growing our sales, customer and engineering teams, with part of their pay held in 4DMedical shares.
Thank you to every shareholder who voted and joined us today. We will keep talking with you about how we reward the people who built this result.

Read the full AGM addresses and presentation: asx.api.cmfyapp.com/asx-research/1…
Andreas Fouras Verified account @AFouras
_ @4DMedicalXV (ASX:4DX) is back at CHEST in Phoenix, Arizona, and a year after our U.S. launch, physicians at our booth are asking how to make CT:VQ® iavailable for their patients.

CHEST is the annual meeting of the American College of Chest Physicians. This week it brought pulmonary and critical care physicians from academic and community hospitals across the country together for late-breaking COPD, asthma, pulmonary hypertension and bronchoscopy data.

1. From first demonstrations to installations
Our booth has been busy all week, with interest in 4DMedical as a whole and in CT:VQ® in particular.

The most common question from physicians is how to get CT:VQ® installed at their own hospital, or via their imaging provider.

2. Leading Academic Medical Centres on board
We launched CT:VQ® in the United States at CHEST 2025 in Chicago.

Since then, leading Academic Medical Centres and outpatient imaging networks have put it into commercial use.

3. Community hospitals asking for SimonMed
Physicians from regional community centres asked how SimonMed could deliver CT:VQ® scans for their patients.

SimonMed runs more than 170 imaging centres across the U.S. and has completed implementation of CT:VQ® at all 125 of their CT enabled clinics under our agreement signed in May.

Thank you to every physician who visited us in Phoenix, and to our U.S. team for four busy days. We look forward to turning these conversations into new CT:VQ® sites.

Read the latest from 4DMedical at conferences and events: 4dmedical.com/news/conferenc…
0:40
Andreas Fouras Verified account @AFouras
4DMedical (ASX:4DX) has released our 2026 Annual Report, covering the year CT:VQ® moved from regulatory clearance to clinical use in leading hospitals.

CT:VQ® is the first and only FDA-cleared technology to show lung perfusion and ventilation without an injected or inhaled contrast agent. It runs on the CT scanners hospitals already have, including rural and community sites without nuclear medicine. The year's milestones:

1. Cleared in major markets, reimbursed in the U.S.
• Medicare reimbursement from CMS followed FDA clearance within days.
• CT:VQ® is now also cleared in Europe, the UK, Canada, Australia and New Zealand.

2. Adopted by leading hospitals and partners
• Stanford, Cleveland Clinic, UC San Diego Health, University of Miami and University of Chicago were among the first U.S. Academic Medical Centres to adopt it.
• Philips now distributes CT:VQ® in North America and SimonMed has introduced it to outpatient imaging across its 170 outpatient imaging sites.

3. Expanding into Europe and new indications
• Our acquisition of contextflow in Vienna gives 4DMedical an established European platform.
• Our CLEAR study is taking CT:VQ® into acute pulmonary embolism, a much larger market than nuclear V/Q.

Across 540 sites, our technology supported more than 344,000 lung scans in FY26, up 77% on the year before. We are just getting started.

 Read the full 2026 Annual Report: asx.api.cmfyapp.com/asx-research/1…
Andreas Fouras Verified account @AFouras
We are proud to partner with @Lungfoundation and support our shared vision of a healthier future for all Australians. That belief sits at the heart of a new multi-year partnership between Lung Foundation Australia and @4DMedicalXV (ASX:4DX).

Together, we share a vision of Healthy Lungs for All - supporting better outcomes for Australians impacted by lung disease and lung cancer. Our partnership will involve:

1. A shared commitment to lung health
• Lung Foundation Australia has spent more than 30 years supporting people living with lung disease and lung cancer.
• 4DMedical is committed to advancing the way respiratory conditions are understood, diagnosed and managed.

2. Putting people at the centre
• Where someone lives or their circumstances should not determine the care and support they can access.
• This partnership is grounded in the belief that every Australian deserves the right care at the right time.

3. Combining trusted support with innovation
• Lung Foundation Australia provides nurses, peer support, social workers, research funding and advocacy.
• 4DMedical’s advanced functional imaging helps clinicians better understand how lungs are working, not simply what they look like.

Meaningful progress in lung health requires collaboration across patients, clinicians, advocates, researchers and technology leaders. We are proud to support Lung Foundation Australia’s important work and help extend its impact across the Australian community.

We look forward to working together to help more Australians breathe easier and live well.
Read the press release from Lung Foundation Australia: lungfoundation.com.au/news/lung-foun…